EICHORCondition: Chronic Kidney Disease · Sponsor: Atom Therapeutics Co., Ltd
This is a phase 2, international, multicenter, randomized, double blind, placebo-controlled trial to evaluate the efficacy and safety of ABP-671 in subjects with CKD and hyperuricaemia, to preliminarily evaluate the efficacy of ABP-671 in the treatment of subjects with CKD and hyperuricemia, primary Efficacy Endpoint is change in UACR from baseline to Week 40
This description comes directly from the study's public registry record.
Renbo Gao · +86 15062305252 · renbo.gao@atombp.com
Always discuss trial participation with your own doctor first.
| Renal Research Gosford Pty Ltd | Gosford, New South Wales, Australia | — |
| Genesis Research services | Newcastle, New South Wales, Australia | — |
| Paratus Clinical Research Brisbane | Brisbane, Queensland, Australia | — |
| Beijing Tsinghua Changgung Hospital | Beijing, Beijing Municipality, China | — |
| Peking University First Hospital | Beijing, Beijing Municipality, China | — |
| Xuanwu Hospital Capital Medical University | Beijing, Beijing Municipality, China | — |
| Jiangsu Province Hospital | Nanjing, Jiangsu, China | — |
| Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine | Shanghai, Shanghai Municipality, China | — |
| Sir Run Run Shaw Hospital , affiliated with the Zhejiang University School of Medicine | Hangzhou, Zhejiang, China | — |
| Zhejiang Provincial People's Hospital | Hangzhou, Zhejiang, China | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07323095